Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340,In Vitro

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

(2011) Calvin Cohen et al.   AIDS

In VitroCharacterization of GS-8374, a Novel Phosphonate-Containing Inhibitor of HIV-1 Protease with a Favorable Resistance Profile

(2011) Christian Callebaut et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir

(2011) Srinivasan Ramanathan et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV

(2010) Polina German et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer

(2010) Lianhong Xu et al.   ACS Medicinal Chemistry Letters

Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity

(2009) A A Mathias et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS